U.S. Markets open in 8 hrs 25 mins

Ebola drug FDA move, Lululemon back in vogue, Zynga gets zapped

Hot Stock Minute

Here are some of the stocks the Yahoo Finance team will be watching for you today.

Tekmira Pharmaceuticals (TKMR) shares soared in early trading after the Canadian drugmaker said the that Food and Drug Administration modified a clinical hold placed on its experimental Ebola drug. The move could enable the company to potentially use the treatment on individuals infected with deadly Ebola virus. Meanwhile, the World Health Organization has declared the outbreak of Ebola in West Africa an international public-health emergency.

Lululemon (LULU) shares rose in the pre-market after its founder Chip Wilson agreed to sell half his stake in the company, or about 14% of the outstanding stock, to private equity firm Advent for $845 million. The deal helps avert a potential proxy war on the yoga-gear maker.

Gap (GPS) shares were up before the bell. The apparel retailer reported same-stores sales rose a better-than-expected 2% in July thanks to growth at its Banana Republic and Old Navy stores, which offset declines at the company's namesake brand. Gap also raised its earnings outlook for the second quarter.

Zynga (ZNGA) shares tumbled in the pre-market. The online game company cut its outlook for the year after it said it will delay the release of several new games. The company also reported earnings broke even last quarter, and revenue missed analysts' estimates. But on a brighter note, Zynga said it's entering the sports category, through licensing deals with the National Football League and Tiger Woods.

Pfizer (PFE) also grabbing headlines this morning. Reuters reported that the company is facing nearly a thousand lawsuits from women who claim Pfizer knew its anti-cholesterol drug Lipitor could give them Type 2 diabetes, but didn't warn the public. In 2012, the Food and Drug Administration said Lipitor and other statins had been linked to a "small increased risk" of diabetes. Lipitor is the best-selling prescription drug, with $130 billion in sales and 29 million patients having taken it since 1996.